Carbuncle
Methodology & AI Transparency ⓘ
Carbuncle Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Carbuncle—coded clinically as L02.93 across Skin & Dermatology guidelines—combines contact/systemic trigger review [Carbuncle L02.93] with structured follow-up of Affected Body Surface in Carbuncle (L02.93: Area (BSA /) (Clear or Almost Clear (IGA 0–1) (L02.93)).
- 2 Real-world patient consensus: Clinical coding for Carbuncle uses ICD-10 L02.93 across Skin & Dermatology specialty care.
- 3 Typical cash cost range: Primary evaluation for Carbuncle incorporates contact/systemic trigger review [Carbuncle L02.93] and symptom diary review.
- 4 Top reported side effects / signs: Longitudinal Carbuncle monitoring tracks 25-Hydroxy Vitamin D in Carbuncle (L02.93: & hs-CRP) toward 25(OH)D 40–65 ng/mL (L02.93).
Ask our AI Specialists anything about Carbuncle
What Is Carbuncle?
Carbuncle—coded clinically as L02.93 across Skin & Dermatology guidelines—combines contact/systemic trigger review [Carbuncle L02.93] with structured follow-up of Affected Body Surface in Carbuncle (L02.93: Area (BSA /) (Clear or Almost Clear (IGA 0–1) (L02.93)).
Pathophysiology, Underlying Causes & Clinical Presentation
Mechanistic hallmarks of Carbuncle (L02.93) center on cutaneous immune skewing in Carbuncle (L02.93: (Th2/IL-4/IL-13 in atopic). targeted skin & dermatology interventions aim to normalize 25-Hydroxy Vitamin D in Carbuncle (L02.93: & hs-CRP).
Common Symptoms & Clinical Signs
- • Presentation of Carbuncle (L02.93): recurrent flares triggered in Carbuncle (L02.93: by UV exposure,)
- • Secondary Carbuncle clinical sign: persistent erythematous plaques, in Carbuncle (L02.93: scaly patches, pruritic)
- • Symptom flares in Carbuncle correlating with 25-Hydroxy Vitamin D in Carbuncle (L02.93: & hs-CRP) deviation outside 25(OH)D 40–65 ng/mL (L02.93)
- • Functional skin & dermatology impact requiring contact/systemic trigger review [Carbuncle L02.93] evaluation (L02.93)
Primary Federal Reference: NIH / National Library of Medicine MedlinePlus Entry ↗
Carbuncle Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | L02.93 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Dermatology: Acne, Eczema, Psoriasis & Rosacea | NIH MedlinePlus Health Topics |
| Diagnostic / Lab Marker: 25-Hydroxy Vitamin D in Carbuncle (L02.93: & hs-CRP) | 25(OH)D 40–65 ng/mL (L02.93) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Affected Body Surface in Carbuncle (L02.93: Area (BSA /) | Clear or Almost Clear (IGA 0–1) (L02.93) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Fasting Lipids & in Carbuncle (L02.93: ALT (if systemic) | Within baseline reference limits (L02.93) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Carbuncle
Treatment selection for Carbuncle depends on clinical severity, diagnostic lab results, and medical history. Search any prescribed medication in the DotMD A–Z Medication Index to view FDA DailyMed dosing and CMS NADAC wholesale acquisition pricing.
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Carbuncle)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| Can This Approach Help? Inside the Latest Research on Benefits and safety of PF-07038124 in Patients With eczema and plaque psoriasis 104 patients were randomized (mean [SD] age, 43.0 [15.4] years; 55 [52.9%] women; 4 [3.8%] Asian, 13 [12.5%] Black, and 87 [83.7%] White), including 70 with AD (41 women [58.6%]; mean [SD] ages, 41.4 [16.6] years in the... JAMA dermatology • 2024-02-01 • Randomized Controlled Trial | N = 104 | 88/100 | PMID 38117526 ↗ |
| What the Latest Evidence Really Says About Phototherapy for eczema: Systematic review and network meta-analysis of Due to possible long-term adverse effects of high-dose UVA1, medium-dose UVA1 cold light appears to be the superior form for AD. Photodermatology, photoimmunology & photomedicine • 2022-05-15 • Meta-Analysis | Multi-cohort | 86/100 | PMID 34653289 ↗ |
| Can This Approach Help? Inside the Latest Research on Clinical implications and predictive values of early PASI responses to Tildrakizumab week 28 nonresponders can be identified by week 16 PASI response. The Journal of dermatological treatment • 2022-05-15 • Phase III Randomized Trial | Multi-cohort | 82/100 | PMID 33678106 ↗ |
Carbuncle Patient Community & “People Like Me” Threads
Filter Carbuncle community threads and patient logs by age, biological sex, dosage, and treatment duration.